Here is the original report that I posted back in July:
southampton.ac.uk/news/2020...
This the update to that trial:
"Interferons are cytokines that modulate immune responses to viral infection. The type I interferons (interferon-α and interferon-β) have been tested against coronavirus infections in vitro, with encouraging results. Antiviral responses mediated by interferon-β have been shown to be compromised in people susceptible to COVID-19, such as older people or those with chronic airway diseases. Furthermore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suppresses cellular interferon production, thus limiting the strength of the initial innate immune response. Exogenous use of inhaled interferon beta-1a in patients with asthma and respiratory viral infections has previously been shown to improve antiviral responses and improve lung function. These properties might facilitate improvement or recovery in patients with SARS-CoV-2 infection—a severe, viral, respiratory disease where the need for an effective therapeutic intervention is paramount. We aimed to evaluate the potential effects of an inhaled interferon beta-1a formulation (SNG001) in patients admitted to hospital with confirmed SARS-CoV-2 infection."